Hematologic Drug Shortage Information

Drug shortages are reaching an all-time high in the United States, especially in hematology care. ASH continues to keep members apprised of shortages as well as actively engage with Congress, federal agencies, including recent discussions with U.S. Food and Drug Administration (FDA), and other stakeholders to ensure continued access to safe and effective hematologic drugs. Please see below the recent hematologic shortages, the Society’s actions, and ways for members to get involved.

Cancer Drug Shortage Consensus Letter

ASH, in partnership with organizations across the cancer community, developed a consensus statement identifying the primary drivers of the persistent drug shortages crisis in the United States and proposing actionable policy solutions to protect access to critical cancer medications.

The statement outlines three priorities that require immediate action to address:

• Increasing transparency across the drug supply chain
• Strengthening incentives for manufacturers to invest in high-quality, redundant supply system
• Stabilizing the generic drug market

Read Drug Shortage Consensus

Current Hematologic Drug Shortages

Discontinued Hematologic Drugs

Resolved Hematologic Drug Shortages

Additional Resources

For more information on drug shortages, visit the FDA drug shortage webpage.
To report a drug shortage to FDA e-mail drugshortages@fda.hhs.gov.
To report concerns about drug price gouging due to shortages, contact FDA's Office of Criminal Investigations.

ASH's Comments to Congress and the U.S. Food and Drug Administration

For more information or to notify ASH of drug recalls or shortages, please contact ASH Policy and Practice Manager, Myra Masood at mmasood@hematology.org.